Critical Insights From Moderna Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed reviews on Moderna (NASDAQ:MRNA) over the past three months, with 7 total ratings ranging from bullish to indifferent. The average 12-month price target for MRNA is now $123.43, down from $157.75, with a high estimate of $231.00 and a low of $69.00. Moderna's financial performance shows challenges, with a -44.5% revenue decline as of September 30, 2023, a net margin of -203.13%, and an ROE of -23.88%. The company's debt-to-equity ratio is low at 0.11, indicating cautious financial management.
January 12, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna's stock may face pressure due to the lowered average price target and the reported financial challenges, including significant revenue decline and low profitability indicators.
The reduction in the average price target by analysts and the negative financial indicators such as a sharp revenue decline and low profitability metrics like net margin and ROE suggest that investor sentiment may be negatively impacted in the short term, potentially leading to a decrease in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100